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ABSTRACT 
Amyloid diseases involve specific protein misfolding events and formation of fibrillar 
deposits. The symptoms of these diseases are broad and dependent on site of accumulation, 
with different amyloid proteins depositing in specific tissues or systematically. One such 
protein is transthyretin (TTR) associated with senile systemic amyloidosis, familial amyloid 
polyneuropathy and familial amyloid cardiomyopathy. We show that the glycosaminoglycan 
heparan sulfate (HS) can be co-localized with TTR in elder myopathic heart tissue and 
identify residue 24-35 of TTR as the binding site of HS. Moreover, we show that heparin, a 
HS homolog, can promote fibril formation and accumulation of TTR using cell cultures and a 
Drosophila in vivo model. 
It has been shown that certain chaperones are associated with amyloid disease and can 
promote or inhibit the aggregation into amyloid. BRICHOS is an approximately 100 residue 
protein domain present in over a 1000 proteins divided into 10 families. BRICHOS 
containing proteins have been ascribed a wide variety of functions and some are associated 
with diseases such as respiratory distress syndrome, dementia and cancer. The BRICHOS 
domains of proSP-C, a precursor protein to lung surfactant protein C, and Bri2, a protein 
associated with familial British and Danish dementia, can act as chaperones and inhibit 
amyloid fibril formation of the amyloid-β peptide (Aβ) of Alzheimer’s disease (AD). We 
show that both proSP-C and Bri2 BRICHOS can prevent aggregation of Aβ in vivo using 
Drosophila melanogaster as a model organism. Moreover, BRICHOS can inhibit the toxicity 
of Aβ, increasing the life span and locomotor activity of the flies. 
We also identify expression of Bri2 in human pancreas and show that Bri2 co-localizes with 
the islet amyloid polypeptide (IAPP) linked to type 2 diabetes (T2D). Furthermore, Bri2 
BRICHOS can inhibit the aggregation of IAPP in vitro and reduce the toxic effects of IAPP 
in cell cultures and in vivo in a Drosophila model. 
These results show that the BRICHOS domain inhibits the aggregation and toxicity of both 
Aβ and IAPP. The BRICHOS domain, in particular the Bri2 BRICHOS domain, could be 
used as a potential pharmaceutical agent in treatment of amyloid diseases. Similar effects on 
both Aβ and IAPP suggest that the BRICHOS domain also could effect the amyloid 
formation and toxicity of other amyloid proteins, which would be an interesting area to 
further investigate.  
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1 INTRODUCTION 
 
1.1#Amyloids#and#amyloid#diseases#
Amyloids are protein aggregates that arise from misfolding of specific proteins (Merlini and 
Bellotti 2003). There are more than 30 human diseases were proteins deposit as fibrillar 
material in organs and tissues, collectively known as amyloidosis (Table 1) (Westermark et 
al. 2007, Sipe et al. 2012, Sipe et al. 2014). Among those are Alzheimer´s disease (AD), 
Parkinson’s disease (PD), Huntington’s disease and type 2 diabetes (T2D), where each 
disease is characterized by a specific amyloid fibril forming protein (Westermark et al. 2007). 
In some amyloid diseases, the proteins deposit in a single organ (localized) such as the brain 
in AD while in e.g. inflammatory-associated amyloidosis deposits are found in multiple 
organs (systemic), such as the liver, spleen and kidneys (Westermark et al. 2007). The classic 
characterization of amyloids is that they exhibit a β-sheet structure and can be identified by 
exhibiting birefringence when stained with Congo red and viewed under polarized light, and 
as rigid fibrils of approximately 10 nm in diameter when viewed with electron microscopy 
(Sipe and Cohen 2000, Westermark et al. 2002). In some cases, the proteins can have an 
inherited ability to be destabilized and form amyloid fibrils, which becomes pronounced in 
elder individuals, like transthyretin (TTR) in patients with senile systemic amyloidosis 
(Saraiva 2001). In other cases, constant high levels of amyloid forming proteins can cause 
disease, which is the case with β2-microglobulin in patients undergoing extended 
hemodialysis (Gejyo et al. 1985, Verdone et al. 2002). The misfolding of amyloidgenic 
proteins can also be caused by mutations in the gene encoding the protein such in e.g. the 
case of the arctic mutation in familial AD (Nilsberth et al. 2001) or the TTRV30M mutation of 
TTR amyloidosis (Saraiva et al. 1984). 
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Table 1. Amyloid diseases, their respective fibril forming proteins and target organs. Adapted from Sipe et 
al, 2014 (Sipe et al. 2014). Variants indicate abnormality such as mutations or polymorphisms. ANS = 
Autonomic nervous system, CNS = Central nervous system, PNS = Peripheral nervous system. 
Fibril protein Amyloid forming protein Target organ 
AL  Immunoglubulin Light Chain All organs except CNS 
AH  Immunoglubin Heavy Chain All organs except CNS 
AA (Apo) Serum Amyloid A All organs except CNS 
ATTR Transthyretin, wild type 
Transthyretin, variants 
Heart, ligaments, tenosynvium 
PNS, ANS, heart, eye, leptomeninges 
Aβ2M β2-Microglobulin, wild type 
β2-Microglobulin, variants 
Musculoskeletal system 
ANS AApoAI Apolipoprotein A I, variants Heart, liver kidney, PNS, testis larynx, skin 
AApoAII Apolipoprotein A II, variants Kidney 
AApoAIV Apolipoprotein A IV, wild type Kidney medulla and systemic 
AGel Gelsolin, variants PNS, cornea 
ALys Lysozyme, variants Kidney 
ALECT2 Leukocyte Chemotactic Factor-2 Kidney, primarily 
AFib Fibrinogen α, variants Kidney, primarily 
ACys Cystatin C, variants PNS, skin 
ABri Bri2, variants CNS 
ADan Bri2, variants CNS 
Aβ Aβ Protein Precursor (APP), wild type, variants CNS 
APrP Prion Protein, wild type, variants Brain 
ACal (Pro) Calcitonin C-cell thyroid tumors 
AIAPP Islet Amyloid Polypeptide Islet of Langerhans 
AANF Atrial Natriuretic Factor Cardiac atria 
APro Prolactin Pituitary prolactinomas, aging pituitary 
AIns Insulin Iatrogenic, local injection 
ASPC  Surfactant Protein C Precursor, variants Lung 
AGal7 Galectin 7 Skin 
ACor Cornedesmosin Cornified epithelia, hair follicles 
AMed Lactadherin Senile aortic, media 
Aker Kerato-epithelin Cornea 
ALac  Lactoferrin Cornea 
AOAAP Odontogenic Ameloblast-Associated protein Odontogenic tumors 
ASem1 Semenogelin 1 Vesicula seminalis 
AEnf Enfurvitide Iatrogenic 
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Viewing amyloid fibrils using a transmission electron microscope reveals a characteristic 
structure of the fibrils (Fig 1) (Cohen and Calkins 1959, Shirahama and Cohen 1967). The 
structure of amyloid proteins consists of a cross-β sheet with β-strands running perpendicular 
to the fiber axis bound to neighboring strands through backbone hydrogen bonds (Fig 1). 
Analysis of microcrystals of amyloid peptides have revealed a double β-sheet where the side 
chains protruding from the two sheets form a tight steric-zipper (Nelson et al. 2005). Brain 
extracts from human AD patients analyzed by solid state nuclear magnetic resonance have 
shown that in vivo fibrils can be structurally different from in vitro fibrils (Lu et al. 2013), 
with differences in orientation of the side-chains, allowing for interaction with other 
molecules in the amyloid structure. Furthermore, it was shown that amyloid fibrils from 
patients with distinct clinical histories can be structurally different. Detailed knowledge of 
molecular structures and interactions further supports the generic nature of fibrils from 
different amyloid proteins (Wasmer et al. 2008, Fitzpatrick et al. 2013). The generic nature 
can be credited to common properties of the polypeptide backbone facilitating the hydrogen 
bonds of the fibril core, and differences in structure resulting from how side chains are 
incorporated into the common fibrillar architecture (Fandrich and Dobson 2002, Chiti and 
Dobson 2006). 
 
Figure 1. Amyloid fibrils are made up of β-sheets. The electron microscopy image on the right shows fibrils 
formed by islet amyloid polypeptide protein (IAPP) associated to type 2 diabetes. Photo by Marie Oskarsson. 
Scale bar represents 200 nm. 
The formation of amyloid fibrils typically follows a sigmoidal reaction time course and is 
generally divided into three phases (Fig 2). The first phase is the lag phase were amyloid 
proteins form oligomers (nuclei) that can promote further fibrillization (Arosio et al. 2015). 
Fibril 
axis
β-strand
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Larger aggregates and amyloid fibrils are present during this phase, though in amounts low 
enough to not be detected using assays such as a thioflavine T (ThT), commonly used for 
studies of the aggregation process (Arosio et al. 2014). The lag phase is followed by the 
elongation phase were protofibrils are formed and rapidly aggregates, forming amyloid 
fibrils. This is detected as a rapid signal increase. Finally, the plateau phase is reached when 
equilibrium between fibrils and precursor is achieved and the signal increase levels out. 
Fibrils can work as templates for monomers, meaning that when monomers interact with 
fibrils the monomers adopt the same cross-β conformation as the preexisting peptides. 
Adding preformed fibrils to a solution during the lag phase promotes fibril formation as a 
result of seeding (Jucker and Walker 2011).  
 
Figure 2. The process of fibril formation. The process starts with a lag phase, were the amount of aggregation 
and fibril formation is too low to be detected. This is followed by the elongation phase, were protofibrils form 
and aggregates into amyloid fibrils, which results in a rapid increase in signal. This is followed by the plateau 
phase, were equilibrium is reach and the signal pans out. 
The typical reaction kinetics of amyloid formation is a feature of nucleated polymerization 
(Serio et al. 2000). In traditional nucleated polymerization, the initial formation of aggregates 
occur from soluble precursor peptides, followed by elongation of fibrils through 
incorporation of additional precursors. However, amyloid formation also includes secondary 
processes, which can be dominant in the contribution to amyloid growth (Knowles et al. 
2009). The formation of new fibrils can be divided into three general processes (Fig 3) 
(Cohen et al. 2013). In the primary pathway, monomers interact, forming oligomers that can 
act as nuclei for the formation of amyloid fibrils. The secondary pathways are either 
monomer-dependent or monomer-independent. Fibril fragmentation is an important 
monomer-independent process, were fragmentation of fibrils increases the amount of fibril 
ends that can generate further growth. Surface catalyzed secondary nucleation is a 
lag phase
elongation phase
plateau phase
Time
Fibril 
amounts
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monomer-dependent process where monomer binding to fibrils catalyze oligomer 
formation. Recently it was shown, by using experimental ThT data and kinetic models that 
the proliferation of toxic oligomers and aggregates of AD mainly occurs through a 
secondary nucleation mechanism (Cohen et al. 2013). 
 
Figure 3. Major fibril formation processes and diagram of pathways. The formation of fibrils can be divided 
into different processes. In the primary nucleation pathway, monomers interact with each other to form 
oligomers and fibrils. Two major secondary pathways are fragmentation, were fibrils fragment and increase the 
number of fibril ends available for binding, and secondary nucleation, were monomers bind to the fibrillar 
surface. The lower part of the figure shows a schematic diagram of primary nucleation and secondary nucleation 
molecular pathways. Adapted from Cohen et al, 2013 (Cohen et al. 2013). 
The amyloid forming proteins make up for the major part of amyloid deposits. However, 
other components can usually be found as well. Three of the more studied components are 
heparan sulfate (HS), serum amyloid P component and Apolipoprotein E (ApoE). HS is a 
glycosaminoglycan (GAG) composed of repeating disaccharide units and is believed to be an 
important player in amyloid fibril formation. HS has been associated with several amyloid 
diseases, affecting processing and promoting fibril formation of amyloid proteins (Leveugle 
et al. 1997). Serum amyloid P component is a protein that can bind to amyloid fibrils (Pepys 
et al. 1979), preventing proteolysis (Tennent et al. 1995) and can be radiolabeled to be used 
Monomer
Oligomer
Fibril
Elongation
+
Positive feedback
Primary processes Secondary processes
FragmentationHomogenous nucleation Secondary nucleation
  10 
for studying amyloid deposits in the human body (Hawkins 2002). Another protein that has 
been found in amyloid deposits is ApoE that has been associated with T2D (Charge et al. 
1996) and AD (Strittmatter et al. 1993).  
1.1.1 Alzheimer´s disease 
AD is the most common form of dementia representing 60-80% of all cases (Alzheimer´s 
Association 2014). It is a neurodegenerative disease and symptoms include memory loss and 
cognitive problems such as disorientation and confusion. AD can be divided into two groups, 
sporadic and familial. Sporadic cases are by far the most prevalent form of AD, making up 
95% of all cases, and familial forms makes up for only a small number of all cases (Blennow 
et al. 2006). There are two aggregated hallmark proteins in AD, Aß and tau (Hardy and 
Selkoe 2002). 
The Aß peptide was first discovered in 1984 (Glenner and Wong 1984) and identified as the 
main component of extracellular amyloid plaques of AD (Masters et al. 1985). The amyloid 
hypothesis postulates that the accumulation of Aß is the primary cause of AD and the other 
parts of the disease process are secondary (Hardy and Selkoe 2002). The precursor protein of 
Aß is APP, a type 1 transmembrane (TM) protein, with the N-terminal located in the ER 
lumen. APP can be processed in two distinct pathways, the amyloidogenic and the non-
amyloidogenic, the difference being the initial proteolytic cleavage. In the amyloidogenic 
pathway, APP is first cleaved by ß-secretase at the N-terminal side of Aß, releasing a soluble 
100 kDa N-terminal fragment and a membrane-bound 12 kDa C-terminal fragment  (Fig 4). 
Further cleavage of the C-terminal fragment by γ-secretase produces the Aß peptides (Haass 
et al. 1993). The dominant species of Aß are Aß40 (40 residues in length) and Aß42 (42 
residues in length), although Aß43 has been shown to be more prevalent in amyloid plaque 
cores of AD patients than Aß40 and shows similar aggregation propensity as Aß42 
(Welander et al. 2009). The non-amyloidogenic pathway instead starts with cleavage of APP 
by α-secretase (Sisodia 1992), generating a soluble N-terminal fragment and a 10 kDa 
membrane-bound C-terminal fragment. Cleavage by γ-secretase of the C-terminal fragment 
produces the p3 peptide (Fig 4) (Haass et al. 1993), which is nonpathogenic. The familial, 
early onset AD cases are linked to mutations in the APP gene, located on chromosome 21 
(Tanzi et al. 1987, Korenberg et al. 1989) or presenilin genes (which are part of the γ-
secretase complex). Several different mutations of the APP gene have been linked to the early 
onset of the disease (Chartier-Harlin et al. 1991, Goate et al. 1991, Mullan et al. 1992), 
affecting the aggregation propensity of the Aß peptide. The gene of presenilin 1 is located on 
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chromosome 14 (Sherrington et al. 1995) and presenilin 2 on chromosome 2 (Rogaev et al. 
1995), and mutations in any of them are linked to early-onset AD. Mutations in presenilin 1 
affect the conformation of presenilin 1 and interaction with APP (Berezovska et al. 2005), 
and mutations in both presenilin 1 and presenilin 2 increase the ratio of Aß42/Aß40 and lead 
to early onset AD (Borchelt et al. 1996, Scheuner et al. 1996). An isoform of ApoE, ApoE4, 
increases the likelihood of developing AD by, among other things, modulating trafficking of 
APP and Aß production (Bu 2009, Yu et al. 2014). 
 
Figure 4. Different pathways in APP processing. APP cleavage by β- and γ-secretase result in the production 
of Aβ peptide, hence known as the amyloidogenic pathway. Cleavage by α- and γ-secretase results in the 
production of the nonpathogenic p3 peptide, known as the non-amyloidogenic pathway. 
Aβ40 is the most abundant form of the Aβ, although research points to the fact that the 
main toxic component is Aβ42 (Younkin 1995). Previously, it was believed that Aβ toxicity 
was due to the plaques formed by aggregation and fibrillization of Aβ. In more recent years 
this theory has been revised and it is now believed that oligomers of Aβ formed during the 
aggregation process are the main reason for toxicity (Walsh and Selkoe 2004). This would 
also explain why certain findings indicate that there is no clear link between amount of 
plaques and clinical symptoms in AD patients (Braak and Braak 1991). The new theories 
about Aβ toxicity are further strengthened by the fact that certain Aβ mutations, which 
leads to early onset of AD, have been shown to produce increased numbers of oligomers 
(Nilsberth et al. 2001).  
!
!
!
TM
!
!
!
TM
!
!
!
TM
AβAPP
β-secretase α-secretase
Aβ
ɣ-secretase
Aβ
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The second hallmark of AD is the presence of intracellular neurofibrillary tangles made of 
hyperphosphorylated tau (Grundke-Iqbal et al. 1986). In contrast to Aβ plaques, the amount 
of neurofibrillary tangles correlate with the clinical symptoms of AD (Braak and Braak 
1991, Goedert and Spillantini 2006). Studies have suggested that synergistic effects of Aβ 
and tau can impair mitochondrial function and energy homeostasis (Rhein et al. 2009). It 
has also recently been suggested that the aggregation and toxicity of the Aβ and tau protein 
have similarities to that of the prion protein (PrP), in that toxic forms can be secreted and 
taken up by surrounding neurons, and misprocessed proteins can be used as a template for 
further aggregation of misfolded proteins (Jucker and Walker 2011, Hall and Patuto 2012). 
Currently, there are no cures or treatments for stopping AD from progressing. Memory 
impairments as well as behavior changes can be treated to some extent with medication. 
However, no real cure has been found despite extensive clinical trials (Schneider et al. 
2014). Almost 200 drugs have reached stage 2 clinical trials, however only cholinesterase 
inhibitors and memantine have been approved as treatments of AD over the past 30 years 
and both show limited effects. Lower synthesis of acetylcholine is associated with reduced 
cognition in dementia and AD (Perry et al. 1978, Francis et al. 1985) and raising the levels 
of acetylcholine increases the expression of acetylcholine receptors (Barnes et al. 2000) and 
is linked to the improvement of other neurotransmitter systems (Francis et al. 1993, Dijk et 
al. 1995). Therefore, by inhibiting the action of acetylcholine-hydrolyzing enzyme 
acetylcholinesterase, the levels of acetylcholine are raised and cholinergic 
neurotransmission can be improved (Giacobini 2003). Memantine is a uncompetitive, 
voltage-dependent glutamate receptor antagonist, with rapid blocking-unblocking kinetics 
and moderate binding affinity (Parsons et al. 1993). These properties allow memantine to 
interact with the glutaminergic signaling system and influence dysfunctional receptor 
activation in AD, which are otherwise overactivated (Danysz et al. 2000). As toxic Aβ 
oligomers have come more into focus as a main culprit behind AD (Hayden and Teplow 
2013), strategizes that are directed to inhibit the aggregation of Aβ have emerged. In animal 
models it has been shown that antibodies against Aβ can improve memory and decrease the 
plaque load (Rasool et al. 2013). One Aβ antibody has been shown to decrease the amount 
of Aβ oligomers in the brain and CSF of a mouse model with no impact on the monomeric 
amounts (Tucker et al. 2015). However, several antibodies have been tested in clinical trials 
and have shown no benefits or even adverse effects in later phases (Schneider et al. 2014). 
Treatment strategizes also include indirectly targeting the Aβ aggregation by affecting the 
processing of APP with α-, β- or γ-modulators. Etazolate, a α-secretase activator have 
shown acceptable safety and tolerability (Vellas et al. 2011), with further clinical trials on-
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going. β-secretase inhibitors have been tested, but development has been impaired by 
problems to cross the blood brain barrier. One β-secretase inhibitor, pioglitazone, showed 
acceptable tolerability, but no beneficial effects (Geldmacher et al. 2011). A γ-secretase 
inhibitor showed no improvement in cognition and was associated with adverse effects 
including skin cancer and infections (Doody et al. 2013). Tramiprosate, a compound 
reducing Aβ aggregation, gave negative results in a phase III trial (Aisen et al. 2011). There 
are currently several pharmaceutical candidates in various stages of clinical trials 
(Schneider et al. 2014). 
1.1.2 Transthyretin amyloidosis 
Transthyretin (TTR) is a protein present in blood and cerebrospinal fluid. It has a molecular 
weight of 14 kDa and appears as a homotetramer in its native state (Blake et al. 1978). 
Functionally, TTR has been shown to transport retinol (Vitamin A) and thyroxine and the 
name transthyretin is derived from thyroxine and retinol (Raz et al. 1970). TTR has also been 
suggested to be involved in development and regeneration of the nervous system (Soprano et 
al. 1985). In TTR amyloidosis the homotetrameric structure is destabilized, which causes the 
release of monomeric TTR subunits that are prone to misfold, aggregate and form amyloid 
fibrils (Quintas et al. 2001, Wiseman et al. 2005). The shift in equilibrium between 
monomers and homotetramers have been shown to be effected by high temperatures and low 
pH, resulting in an increased amount of monomers (Kelly et al. 1997). Over 100 point 
mutations have been associated with hereditary forms of disease (Connors et al. 2003) and 
these familial forms are often lethal. Several mutations are associated with destabilization of 
the homotetrameric form of TTR, leading to an increase in monomer content, resulting in 
amyloid formation (Hammarström et al. 2002). Mutations also affect where TTR is deposited 
in the body. Wild type TTR is mostly found as amyloid inclusions in the heart (Westermark 
et al. 1990), but is also found in liver and lungs (Pitkanen et al. 1984). The most common 
mutant TTRV30M (Saraiva et al. 1984) is found as amyloid inclusion in the peripheral nervous 
system and gastrointestinal tract (Saraiva et al. 1984). The TTRV122I mutation (Gorevic et al. 
1989) is found exclusively as amyloid deposits in cardiac tissue and is carried by 4% of the 
African-American population (Jacobson et al. 1996). TTR is primarily produced in the liver 
and therefore a liver transplant can be used to replace the expression of mutated variants of 
TTR with wild type TTR, preventing neuropathy to some extent (Holmgren et al. 1991). In 
recent time, stabilizing the homotetramer of TTR with a small molecular compound has 
shown promise as a viable option to prevent amyloid inclusion and toxicity of TTR (Bulawa 
et al. 2012). 
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1.1.3 Diabetes mellitus 
Diabetes mellitus is a group of diseases affecting over 380 million people (Guariguata et al. 
2014) and is characterized by the lack of, or dysfunction of insulin and disturbed glucose and 
lipid metabolism. The two major forms are type 1 (T1D) diabetes and T2D. In T1D or 
juvenile diabetes the insulin producing β-cells are targeted through an autoimmune response, 
leading to decreased production of insulin (van Belle et al. 2011). The most common form of 
diabetes is T2D also known as adult-onset diabetes, which makes up for 90% of all diabetes 
cases. Development of T2D is affected by a number of genetic and environmental factors, 
such as age, obesity, diet and lifestyle. The disease is caused either by dysfunction of insulin 
producing β-cells or the failure of cells to respond to insulin secretion. Islet amyloid 
polypeptide (IAPP) is a 37 residue peptide (Westermark et al. 1987) naturally expressed in 
the β-cells of Langerhans islets and stored in secretory granules together with insulin 
(Lukinius et al. 1989). Several functions have been ascribed to IAPP, including effects on 
secretion of insulin (Gebre-Medhin et al. 1998), pain reduction (Huang et al. 2010) and 
involvement in calcium homeostasis (Dacquin et al. 2004). The insulin producing β-cells are 
found in the islet of Langerhans and in T2D patients amyloid deposits containing IAPP have 
been found within these islets (Westermark et al. 1986, Westermark et al. 1987). IAPP can 
form toxic oligomers, which can reduce the number of insulin producing β-cells (Gurlo et al. 
2010). The working hypothesis of IAPPs toxicity is that the aggregation starts inside the cells 
and is then spread out from the cells, causing toxicity to surrounding cells (Paulsson et al. 
2006). GAGs such as HS have also been shown to bind IAPP (Watson et al. 1997, Castillo et 
al. 1998), promoting fibril formation. 
1.1.4 Other amyloid diseases 
In Parkinson´s disease (PD), the protein α-synuclein is the major component of the abnormal 
aggregates called Lewy bodies (Spillantini et al. 1997). Although the Lewy bodies and α-
synuclein fibrils are hallmarks of PD, recent research points to oligomers of α-synuclein 
having a significant toxicity and can cause cell death (Outeiro et al. 2008, Nasstrom et al. 
2011, Winner et al. 2011). 
Prion diseases are a group of diseases including Creutzfeldt-Jakob, bovine spongiform 
encephalopathy, scrapie, fatal familial insomnia and kuru (Liberski 2012) The prion diseases 
were first thought to be caused by a virus, but were later found to be caused by a specific 
protein that was named prion (from proteinaceous infectious particle) (Prusiner 1982). The 
prion is distinguished from other amyloid proteins because it can be transferred from one 
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individual to another by uptake of the misfolded PrP. The incubation periods of the prion 
diseases are usually long, but once symptoms appear, the disease can progress rapidly. Other 
amyloid proteins such as Aβ have also been suggested to have prion-like properties, such as 
seeding and cell-to-cell transmission of soluble oligomeric Aβ (Nath et al. 2012, Jucker and 
Walker 2013). 
The most common localized amyloid is aortic medial amyloid and amyloid inclusions of this 
variant can be found in basically everyone over the age of 55 (Westermark and Westermark 
2011). A cleavage product of the glycoprotein lactadherin, medin is the major component of 
amyloid inclusions in of the disease (Häggqvist et al. 1999). The 50 residue long peptide has 
been shown to form fibrils in vitro and the last 18-19 amino acids constitute the amyloid-
promoting region (Larsson et al. 2007). 
1.2 MOLECULAR CHAPERONES 
Proteins need a certain three dimensional fold in order to function correctly, however proteins 
are in risk of misfolding and aggregating, which can lead to loss of function and toxic 
oligomers forming (Hartl et al. 2011). Proteins go through many different conformations, 
while they fold into their native state. The free energy landscape of protein folding is usually 
illustrated as a funnel that the protein travels down into to reach its native folded state (Fig 5) 
(Jahn and Radford 2005). However, the ruggedness of the energy landscape can result in 
proteins ending up locked in non-native, non-functional conformations. Aggregation and 
fibril formation are examples of this phenomenon and the amyloid fibril is considered to 
represent a global minimum of free energy. 
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Fig 5. Schematic picture of funnel-shaped free energy landscape that proteins travel during folding. 
Images of native folded protein and amyloid fibrils were produced with VMD version 1.9.2 from structural data 
(www.pdb.org, PDB ID 1Z0Q (Tomaselli et al. 2006), 3G7W (Wiltzius et al. 2009) and 2BEG (Luhrs et al. 
2005)). Adapted from Jahn and Radford, 2005 (Jahn and Radford 2005). 
In order to prevent misfolding of proteins, cells need chaperones to assist in the folding of 
proteins (Hartl et al. 2011). The definition of a chaperone is a protein that can interact with, 
stabilize or help another protein to fold without being incorporated in its final structure (Hartl 
1996). Proteins can misfold and aggregate due to cellular stress, including mutations, 
temperature changes, pH changes and ageing. Because several chaperone families are 
upregulated as a response to temperature increase, they are known as heat shock proteins 
(HSPs). There are six different families of HSPs, traditionally named after their molecular 
weight (Muchowski and Wacker 2005). The six families are HSPH (also known as HSP110), 
HSPC (HSP90), HSPA (HSP70), HSPD/E (HSP60/HSP10), DNAJ (HSP40) and HSPB 
(small HSP) (Kampinga et al. 2009). HSPA chaperones are important proteins in protein 
folding and proteostasis control and they contain an ATP-binding domain and a C-terminal 
substrate-binding site. HSPA, along with its co-chaperone DNAJ, have been shown to be 
involved in assembly of proteins into macromolecular complexes, prevention of protein 
aggregation and protein degradation (Broadley and Hartl 2009). Both HSPA and HSPC can 
inhibit aggregation of Aβ in vitro. HSPDs, also known as chaperonins, are large double-ring 
complexes that function by enclosing and folding substrate proteins up to sizes of around 60 
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kDa. The HSPD counterpart in E.coli, GroEL, has been shown to interact with at least 250 
different proteins (Kerner et al. 2005). The human protein DNAJB6, belonging to the DNAJ 
family, was recently shown to inhibit the fibril formation of Aβ42 in vitro (Mansson et al. 
2014). HSPBs are involved in several human diseases (Kampinga and Garrido 2012) and 
have been shown to reduce toxicity of Aβ oligomers in a transgenic mouse model (Ojha et al. 
2011). There are also extracellular chaperones, such as clusterin (also known as 
Apolipoprotein J). Clusterin is a 75-80 kDa heterodimeric protein that can interact with a 
wide range of molecules and has shown to be involved in apoptotic disease states such as 
neurodegeneration (Jones and Jomary 2002). Clusterin can also inhibit the aggregation and 
fibril formation of Aβ and α-synuclein (Yerbury et al. 2007). 
1.3 THE BRICHOS DOMAIN 
The BRICHOS domain was discovered by Sanchez-Pulido et al in 2002. The name was 
derived from three of the protein families containing BRICHOS domains, Bri, 
Chondromodulin-1 and surfactant protein C (SP-C) (Sanchez-Pulido et al. 2002). The 
BRICHOS family was expanded in 2009, when it was found that BRICHOS domains are 
present in over 300 proteins (Hedlund et al. 2009) divided into 10 families (Fig 6). 
 
Figure 6. The BRICHOS family tree. The distance between the different families reflects their evolutionary 
separation. Image taken from Knight et al, 2013 (Knight et al. 2013) and reproduced with author’s permission. 
The BRICHOS domain is around 100 amino acids long and although the sequence similarity 
between different species is low, predicted structures of the BRICHOS domains are similar 
and they share some common motifs (Sanchez-Pulido et al. 2002, Hedlund et al. 2009). The 
N-terminal part of BRICHOS containing proteins is a cytosolic region, followed by a TM 
region, a linker, a BRICHOS domain and finally a C-terminal part (Fig 7). This is true for all 
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BRICHOS containing proteins with the exception of proSP-C, which lacks the C-terminal 
part. Moreover, all BRICHOS containing protein have a region of high ß-sheet propensity in 
the C-terminal part, whereas in proSP-C, the TM region instead has a high ß-sheet propensity 
(Willander et al. 2011). The overall sequence similarities are low between different 
BRICHOS domains, with only three amino acids being generally conserved, one Asp and two 
Cys (Sanchez-Pulido et al. 2002). The two Cys residues have been shown to form a 
disulphide bridge in proSP-C (Casals et al. 2008), which indicates that this is likely the case 
in other BRICHOS containing proteins as well.  
 
Figure 7. The general structure of a BRICHOS containing protein. The structure begins with an N-terminal 
region, followed by a TM region, a linker region, the BRICHOS domain and a C-terminal part. Most BRICHOS 
proteins share this structure with an exception being proSP-C, which lacks the C-terminal part. 
The only structure of a BRICHOS domain currently available is the crystal structure of 
proSP-C BRICHOS (Willander et al. 2012a). The structure of proSP-Cs BRICHOS domain 
shows a unique folding motif (Willander et al. 2012a), where five β-strands form the central 
part. The central β-sheet is flanked by one α-helix on either side, one on face A of the protein 
and one on face B (Fig 8). Conserved residues and interstitial lung disease (ILD) associated 
mutations suggest that face A is involved in peptide binding. The hydrophobic surface of face 
A is normally blocked by α-helix 1, but molecular dynamic simulations showed that the 
movement of this α-helix makes the surface accessible for interaction with substrates 
(Willander et al. 2012a). Exposed side-chains of face A correlate with the assumed target 
peptides properties, which was first observed from comparison of proSP-C and Bri2. The 
postulated target region of the BRICHOS domain of proSP-C is the hydrophobic TM part and 
the face A of the proSP-C mainly consists of hydrophobic residues (Willander et al. 2012a). 
Bri2 BRICHOS on the other hand binds the C-terminally released peptide of Bri2, Bri23 
(Peng et al. 2010), which is more polar and contains charged residues. In correlation with 
this, face A of Bri2 BRICHOS contains charged residues were proSP-C has hydrophobic 
residues. Other BRICHOS domains can also be modeled based on the proSP-C BRICHOS 
structure, and Bri family proteins and gastrokines show correlation between the target peptide 
and the proposed binding site (Knight et al. 2013). 
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Figure 8. The structure of the BRICHOS domain of proSP-C. The structure has a unique fold and is 
composed of a five-stranded β-sheet and one α-helix on each side of the β-sheet. Image produced with VMD 
version 1.9.2 from the structural data (www.pdb.org, PDB ID 2YAD (Willander et al. 2012a)). 
The BRICHOS domain has been suggested to have a chaperone-like function towards the ß-
sheet propensity region in BRICHOS containing proteins (Willander et al. 2012a, Knight et 
al. 2013). In papers II-IV of this thesis, the effects of two BRICHOS domains, proSP-C and 
Bri2, on amyloid aggregation and toxicity have been studied. 
1.3.1 ProSP-C 
ProSP-C is the precursor protein to lung surfactant protein C (SP-C) and is a type 2 TM 
protein (N-terminal part located in the cytosol) (Keller et al. 1991). The function of lung 
surfactants is to lower the surface tension of the water-air interface and prevent lung collapse 
at the end of expiration (Whitsett and Weaver 2002). The precursor form is expressed as a 
197 amino acid protein. A multistep cleavage process generates mature SP-C, starting with 
cleavage of the C-terminal ER luminal part, followed by cleavage of the N-terminal part 
(Beers et al. 1994, Johnson et al. 2001, Solarin et al. 2001). As a result, the 35 residue mature 
form of SP-C is produced. Mutations in the proSP-C gene (SFTPC) are associated with ILD 
(Nogee et al. 2001, Nogee et al. 2002), of which 55% are spontaneous mutations, while 45% 
are inherited (Hamvas 2006). The severity of disease and age of onset can vary between 
individuals with the same mutation (Hamvas 2006). Most mutations are located in the linker 
region or the BRICHOS domain, with I73T, a linker region point mutation, being the most 
common (Wert et al. 2009). It has been shown that I73T and Δ91-93 give rise to ILD with 
amyloid deposits in the lung tissue (Willander et al. 2012a). 
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The mature SP-C forms an α-helix and is inserted into the ER membrane. The α-helix 
structure of SP-C is stable when it is located in the membrane, but outside of the membrane 
the peptide can rapidly aggregate and form amyloid fibrils (Szyperski et al. 1998, Gustafsson 
et al. 1999). This is due to that the TM mature part of SP-C is primarily composed of Ile and 
Val, residues with a high β-sheet propensity (Kallberg et al. 2001) and therefor have high 
likelihood to form amyloid (Johansson et al. 2010). Replacing these residues in SP-C with a 
poly-Leu stretches with a higher α-helical propensity, results in a stable α-helical 
conformation (Nilsson et al. 1998) and this peptide that can be used to make a synthetic lung 
surfactant (Johansson et al. 2003). In order for the TM segment to fold correctly it has been 
suggested that the BRICHOS domain of proSP-C can act as molecular chaperone and 
facilitate formation of its α-helical fold (Willander et al. 2012a). This is supported by the fact 
that many mutations causing amyloid deposition and ILD are located in the BRICHOS 
domain. The crystal structure of proSP-C BRICHOS domain showed a trimer, which is also 
supported by analytical ultracentrifugation, size exclusion chromatography, native gel 
electrophoresis and electrospray mass spectrometry (Casals et al. 2008, Willander et al. 
2012a). Molecular dynamics simulations suggests that the monomer is the active from, 
because helix 1 on face A needs to move away from the hydrophobic binding site to be 
exposed, which can not occur in the trimer (Willander et al. 2012a). Comparing the properties 
of face A of other BRICHOS families to their putative client peptides support that the trimer 
is an inactive storage form, while the monomer is the active form (Knight et al. 2013). 
Dissociation of trimeric proSP-C BRICHOS into monomers increases the capacity to inhibit 
Aβ42 fibril formation (Biverstal et al. 2015), supporting the theory that the monomer of 
BRICHOS is the active form. 
The BRICHOS domain of proSP-C has been shown to prevent aggregation and fibril 
formation of the Aβ peptide of AD (Johansson et al. 2009, Nerelius et al. 2009a, Willander et 
al. 2012b). The BRICHOS domain interacts with Aβ, maintaining Aβ as an unstructured 
monomer for an extended time period thereby delaying fibrillization (Willander et al. 2012b). 
Recent data suggest that the proSP-C BRICHOS domain delays the fibril formation by 
binding to fibrils and blocking the secondary nucleation of Aβ42 (Fig 9) (Cohen et al. 2015). 
This alters the aggregation process of Aβ42, and the process proceeds through primary 
nucleation and elongation alone. Since the secondary nucleation has been shown to be a 
major source of oligomers during Aβ42 aggregation (Cohen et al. 2013), the effects of 
BRICHOS is a substantial reduction in the amounts of toxic oligomers created (Fig 9).  
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Figure 9. BRICHOS inhibits formation of toxic Aβ42 oligomers. Diagram of molecular pathways involved in 
Aβ42 fibril formation. BRICHOS binds to fibrils and inhibits the secondary nucleation, thereby preventing the 
major source of oligomer formation. Adapted from Cohen et al, 2015 (Cohen et al. 2015). 
1.3.2 Bri2 
Bri2 is a type 2 TM protein encoded by the gene integral transmembrane protein 2 B 
(ITM2B) (Deleersnijder et al. 1996). It belongs to the same family as Bri1 (ITM2A) (Pittois 
et al. 1999) and Bri3 (ITM2C) (Vidal et al. 2001) and is expressed both in the brain and 
several peripheral tissues. The initially produced, full length Bri2 is 266 amino acids long. 
Bri2 is cleaved in the secretory pathway by furin in the C-terminal part (Kim et al. 2002), 
which produces a 243 residue, mature Bri2 and a small, C-terminal peptide (Bri23) (Fig 10) 
(Kim et al. 1999). The mature Bri2 is cleaved by ADAM10 and the BRICHOS domain is 
subsequently secreted into the extracellular space. The remaining N-terminal part undergoes 
intramembrane proteolysis by SPPL2a/b (Martin et al. 2008). Mutations in the Bri2 gene can 
lead to the release of elongated C-terminal peptides, which can cause amyloidosis. In familial 
British dementia (FBD), a single base substitution leads to a 34 amino acid long amyloid 
peptide (ABri) being released (Vidal et al. 1999). In familial Danish dementia (FDD), a 
decamer duplication insertion causes a reading-frame shift and subsequent release of a 34 
amino acid peptide (ADan) (Vidal et al. 2000). Both ABri and ADan can form fibrils and 
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deposit in the brain. However it has been suggested that ABri/ADan amyloid formation does 
not cause FBD/FDD, but rather the loss of function of Bri2 and concomitant effects on APP 
processing (Tamayev et al. 2010a, Tamayev et al. 2010b). Mouse models of both FBD and 
FDD have shown reduced expression of mature Bri2 and severe hippocampal memory 
deficits, but no signs of cerebral amyloidosis or taupathy. Moreover, Bri2+/- show similar 
deficits as the FBD/FDD mice, and memory loss in FDD mice can be prevented by co-
expression of wild type Bri2. Bri2 has also been found to co-localize with Aβ in amyloid 
plaques, suggesting interaction during the misfolding and aggregation process (Tomidokoro 
et al. 2005, Del Campo et al. 2014). Mature Bri2 has also been shown to inhibit APP 
processing by interacting with secretases and reducing their access to APP in the intracellular 
compartments where APP is processed (Matsuda et al. 2011). Moreover, Bri2 has been 
recognized as one of the 20 most important mediators in ApoE4 carriers and late-onset AD 
patients (Rhinn et al. 2013). 
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Figure 10. Processing of Bri2. The full length Bri2 is first cleaved by furin, producing the mature form and 
Bri23. Processing by ADAM10 releases the BRICHOS domain and the N-terminal part is subsequently cleaved 
by SPPL2a/b. 
The structure of Bri2 BRICHOS has not been determined, however a homology model has 
been created based on data from the crystal structure of proSP-C BRICHOS (Willander et al. 
2012b). This model suggests that the Bri2 BRICHOS has a similar structure as proSP-C 
BRICHOS, with a highly conserved central β-sheet core region. 
Like proSP-C BRICHOS, Bri2 BRICHOS can interact with Aβ peptides, delaying fibril 
formation (Peng et al. 2010, Willander et al. 2012b). Moreover, Bri2 BRICHOS seems to be 
more effective in preventing Aβ aggregation than proSP-C BRICHOS (Willander et al. 
2012b). Bri2 can also interact with APP and affect Aβ production (Fotinopoulou et al. 2005, 
Matsuda et al. 2005, Kim et al. 2008, Matsuda et al. 2008) and a fusion protein of Aβ and 
Bri2 expressed in a mouse model showed completely intact cognitive performance, in sharp 
contrast to APP expressing mice (Kim et al. 2013). 
1.3.3 Other BRICHOS families 
As previously mentioned, BRICHOS containing proteins can be divided into 10 distinct 
groups. Apart from Bri2, there are two more families of Bri proteins. Bri1 is a 263 residue 
long protein and has been linked to chondrogenic differentiation (Deleersnijder et al. 1996, 
Van den Plas and Merregaert 2004). Bri3 is mostly expressed in the brain (Vidal et al. 2001) 
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and proteolytically cleaved by furin in the same manner as Bri2 (Wickham et al. 2005). 
Furthermore, Bri3 has been shown to co-localize and co-immunoprecipitate with APP and 
overexpression of Bri3 reduces cleavage of APP by α- and β-secretase by blocking the target 
site of the secretases (Matsuda et al. 2009).  
There are three families of gastrokines, GKN1, GKN2 and GKN3. GKN1 is expressed in 
gastric mucosa (Martin et al. 2003) and has been associated to gastric cancer. It is highly 
conserved and suggested to be important in mucosal protection (Oien et al. 2003, Oien et al. 
2004). GKN1 has also been shown to inhibit amyloid formation of Aβ40 (Altieri et al. 2014). 
GKN2 is just like GKN1 expressed in gastric mucosa and associated to gastric cancer. It has 
been shown to interact with TFF1 and TFF2, members of trefoil factor family. GKN2 can 
form a heterodimer with TFF1 in humans (Westley et al. 2005) and the mouse homolog has 
been found to bind to TFF2 (Otto et al. 2006). GKN3 is a recently discovered group of 
gastrokines in mice, and associated to gastric atrophy (Otto et al. 2006). The human homolog 
seems to have become non-functional due to mutation resulting in a premature stop-codon. 
Group C is a poorly characterized family of BRICHOS containing proteins that has been 
found in organism all the way down to Drosophila melanogaster and shows a high 
conservation in the C-terminal part (Hedlund et al. 2009). The protein is suggested to be 260 
amino acids in humans and to have a N-glycosylating site. Chondromodulin-1 (ChM-1), also 
known as leukocyte cell-derived chemotaxin, is a 335 residues precursor protein. Processing 
through glycosylation and cleavage by furin renders a 28 kDa glycoprotein (Azizan et al. 
2001). ChM-1 has been linked to chondrosarcoma and loss of ChM-1 expression effect 
suppression of tumor angiogenesis and growth (Hayami et al. 1999). Tenomodulin is a 
protein similar to ChM-1 and has found to be expressed in eye, skeletal muscle and whole rib 
of adult mouse. Elevated levels of expression have also been noted in mouse embryonic 
development (Shukunami et al. 2001, Yamana et al. 2001). Arenicin is an anti-microbial 
peptide found so far only in worms, for which the structure of the C-terminal peptide has 
been solved (Lee et al. 2007, Andra et al. 2008). It has been suggested that arenicin induces 
apoptosis through accumulation of intracellular reactive oxygen species and mitochondrial 
damage in fungal cells (Cho and Lee 2011). 
1.4 DROSOPHILA MELANOGASTER 
Drosophila melanogaster, commonly known as the fruit fly, is a fly species of the 
Drosophilidae family. It has been used extensively in research fields including genetics, 
physiology, biochemistry and evolution science. There are several advantages in using 
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Drosophila as a model system. Flies are easy to handle and don’t require a lot of space, and 
costs are in general low. The flies only have four chromosomes, three autosomes and one sex 
chromosome. Female flies can produce up to 100 eggs per day, making generation of large 
numbers of flies easy. Males and females are also easily distinguishable under a light 
microscope. Meiotic recombination is not present in the males, which makes it easier to avoid 
unwanted recombination when crossing flies. A number of balancer chromosome fly lines 
can be used to avert unwanted recombination. A balancer chromosome is essentially a 
product of multiple chromosomal inversions. Homozygote balancer chromosomes lead to 
non-viable flies as do recombination of the inverted regions with non-balancer chromosomes. 
Balancer fly lines are usually also coupled to a specific phenotypical marker, which ensures 
that flies of different genotypes can be distinguished by external phenotypes such as curly 
wings, stubble hairs or eye color (Fig 11). Many analogs to human proteins exist in 
Drosophila and about 80% of disease related genes have a counterpart in the Drosophila 
(Reiter et al. 2001). Studying and using Drosophila melanogaster flies as a model system has 
a long scientific tradition and tracks back to the beginning of the 20th century. Many 
important scientific discoveries have been made using Drosophila as a model in research on 
hereditary effects, diseases, learning, and signaling pathways among others. In 1908, T.H 
Morgan selected Drosophila as a model of heredity. Among his findings were that the eye 
color was sex linked and the gene controlling this was located on the X chromosome 
(Morgan 1910), and this and other discoveries led to Morgan being awarded the Nobel Prize 
in 1933. In 1913, A.H. Sturtevant constructed the first genome map and was able to show that 
genes are arrange in a linear fashion (Sturtevant 1913). In 1917, H.J. Muller introduced 
balancers in Drosophila research (Muller 1918) and in 1927 he was able to show genetic 
damage and mutation in Drosophila using ionizing radiation (Muller 1927). The later 
discovery resulted in him winning the Nobel Prize in 1946. In 2000 the whole genome of 
Drosophila was sequenced (Adams et al. 2000). In 2011, the Nobel Prize in Physiology or 
Medicine was awarded to J. Hoffman for research about the innate immunity. Using a 
Drosophila model Hoffman demonstrated that the Toll gene was necessary for combating 
fungal infection by identifying pathogenic microorganism and triggering the immune 
response (Lemaitre et al. 1996). 
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Figure 11. Balancer phenotypes in Drosophila flies. The top row shows the wild type phenotypes and the 
bottom row the balancer phenotypes. The hairy shoulders phenotype adds additional hairs to the “shoulder” area. 
The stubble phenotype makes the hairs on the flies’ backs shorter and thicker. The curly phenotype makes the 
wings curl instead of being straight like in wild type flies. 
One of the more important developments in the Drosophila field is the introduction of the 
Gal4/UAS system (Brand and Perrimon 1993). The essential principle of this system is that a 
gene of interest is placed downstream of an upstream activating sequence (UAS), which is 
inserted into the fly genome by injection of a target vector into fly embryos. The gene of 
interest will not be expressed with this insert alone and to achieve expression, the 
transcription factor Gal4 is needed (Brand and Perrimon 1993). Expression of the transgene is 
promoted when Gal4 binds to the UAS. Gal4 is not naturally present in the Drosophila, as it 
is derived from Saccharomyces cerevisiae. Expression is achieved by crossing the responder 
line with a driver line, which has a cell or tissue specific expression of Gal4. As Gal4 is 
needed for expression of the gene of interest, the expression of the transgene will only occur 
in the cells with Gal4 (Brand and Perrimon 1993). Crossing the same responder line with 
different Gal4 driver lines can therefore generate flies with different expression levels and 
locations (Fig 12). This also allows for high toxicity genes to be studied, as the genes can be 
kept silent in the responder flies until crossed with driver flies. The expression of Gal4 is 
temperature dependent and higher temperatures results in higher expression levels (Duffy 
2002). Several different UAS dependent genes can be combined in the same fly for studying 
co-expression of different proteins. Today, there are thousands of fly lines using the 
UAS/Gal4 system available. One of the most common drivers is the ElavC155 driver, which 
gives a pan-neuronal expression of Gal4 (Lin and Goodman 1994). Another commonly used 
driver is the glass multimer reporter (GMR) driver (Freeman 1996), which has a primary eye-
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specific expression profile. The expression of a reporter such as green fluorescence protein 
(GFP) can also be incorporated into a driver line, which can be utilized to investigate which 
cells or tissues that express the gene of interest. The UAS system cannot only be used to 
induce expression, as several UAS controlled RNAi lines have been created and utilized. In 
this instance, the Gal4 is instead used to specifically suppress the expression of a certain gene 
(Brand and Perrimon 1993). 
 
Figure 12. The UAS Gal4 system. When a female fly carrying the transgene of interest (in this case BRICHOS) 
is crossed with a Gal4 expression male fly, the resulting progeny containing both the UAS BRICHOS transgene 
and the Gal4 driver will express the BRICHOS domain. In other possible outcomes, the BRICHOS protein 
cannot be expressed. The white eye phenotype of the flies with only balancer results from this phenotype lacking 
transgene insert, which contains the element for red eye color. 
1.4.1 Models of amyloid disease in Drosophila 
1.4.1.1 Models of Alzheimer´s disease 
There are several Drosophila models of amyloid diseases available. For Alzheimer´s disease, 
several models has been created and utilized in different manners. One strategy has been to 
create transgenic strains expressing human Aβ peptides with different length and mutations 
(Iijima et al. 2004, Crowther et al. 2005). In these models it has been shown that Aβ42 and 
Aβ42E22G (also known as the artic mutant) causes toxicity, reducing the locomotor activity 
and life span of the flies when expressed in the CNS. Aβ42E22G was also shown to be the 
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more toxic variant, with enhanced effects compared to the wild type Aβ42 (Crowther et al. 
2005). Expression of Aβ42 in the eyes of the flies led to retinal degeneration. In another 
study, flies expressing two copies of Aβ42 fused together via a short linker (a tandem 
construct) were generated. Expression of the tandem constructs show highly reduced life 
span, malformation of eyes, increased deposition of Aβ42 and higher levels of soluble 
oligomers (Speretta et al. 2012). The malformation of the eyes in this model is shown in Fig 
13. Another approach for studying Alzheimer´s disease and Aβ toxicity has been to develop 
flies expressing human APP together with BACE (β-secretase) to replicate the processing of 
APP into Aβ peptides. Constructing flies with targeted expression of APP, BACE and 
presenilins, the effects of APP with and without processing could be compared. It was found 
that APP with expression of BACE and presenilins lead to age-dependent neurodegeneration 
due to generation of toxic species, whereas expression of full length APP only did not have 
severe negative effects on the flies (Greeve et al. 2004). Aβ42 Drosophila models have been 
used in a number of studies aimed at finding inhibitors of Aβ aggregation and toxicity. One 
strategy includes co-expressing engineered proteins binding Aβ42 (Luheshi et al. 2010), 
which showed to be effective inhibitors for Aβ42 toxicity, increasing the life span and 
locomotor activity of the flies. Furthermore, the amount of insoluble Aβ was reduced. 
Another strategy is to feed the flies compounds mixed with their normal food. Curcumin was 
fed to flies in one study and the flies showed increased activity and life span when compared 
to flies only expressing Aβ42 or Aβ42E22G (Caesar et al. 2012). Interestingly, this study also 
showed that curcumin does not decrease the fibril formation, but rather accelerates the 
process. The reduced toxicity was therefore ascribed to curcumin reducing levels of toxic 
Aβ42 oligomers. In another study, synthetic ligands binding and stabilizing Aβ in a α-helical 
conformation were fed to Aβ42 expressing flies, which led to increased life span and reduced 
eye tissue destruction (Nerelius et al. 2009b). 
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Figure 13. Aβ42 causes toxicity in flies. Expression of a tandem Aβ42 construct causes severe malformation of 
the eyes compared to the control flies (Speretta et al. 2012). 
1.4.1.2 Transthyretin expressing flies 
Drosophila models of familial amyloid polyneuropathy have been made by creating 
transthyretin expressing flies. Both wild type and mutants such as TTRV30M have been 
created, along with an extra aggregation prone engineered double mutant variant 
TTRV14N/V16E (Pokrzywa et al. 2007). Expression of TTRV30M and TTRV14N/V16E lead to 
decreased life span, neurodegeneration, reduced locomotor activity and eye tissue damage 
(Pokrzywa et al. 2007, Berg et al. 2009). 
1.4.1.3 IAPP expressing flies 
A model for studying T2D amyloidosis has been created (Schultz et al. 2011). In this work 
three different transgenic fly lines were created, expressing human proIAPP, human IAPP 
and non-amyloidogenic mouse IAPP. Only proIAPP reduced the life span of the flies, 
whereas human IAPP and mouse IAPP had no significant effects. Aggregates of both human 
proIAPP and human IAPP could be detected in the CNS and in fat bodies of the fly head 
(Schultz et al. 2011). The accumulation of human proIAPP and human IAPP in the fat bodies 
was further characterized and shown to result in structurally organized granules with a 
pentagonal rod-like structure (Schultz et al. 2011). 
1.4.1.4 α-synuclein expressing flies 
A Drosophila model of PD was published in 2000 (Feany and Bender 2000). In this model, 
wild type or mutant forms of α-synuclein are expressed leading to intraneuronal inclusions, 
decreased locomotor activity and eye degeneration (Feany and Bender 2000). All variants 
Control Tandem Aβ42
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showed similar toxicity. Co-expression of HSPA and α-synuclein in dopaminergic neurons in 
flies was later shown to protect against α-synuclein-induced neuronal degeneration (Auluck 
et al. 2002).  
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2 AIMS OF PRESENT INVESTIGATION 
The overall aim of this thesis was to study amyloid diseases and investigate the effects of the 
BRICHOS domain on aggregation and toxicity of amyloid proteins. More specifically, we 
used Drosophila models to achieve these goals. The specific objectives were as follows: 
Paper I: To characterize possible HS interactions with TTR and effects on aggregation. 
Papers II and III: To study the effects of proSP-C and Bri2 BRICHOS on Aβ aggregation and 
toxicity in vivo using a Drosophila model system 
Paper IV: To investigate possible association of Bri2 and IAPP in human pancreatic islets and 
study the effects of Bri2 BRICHOS on IAPP aggregation and toxicity in vitro and in vivo 
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3 MATERIALS AND METHODS 
More detailed descriptions about the materials and methods used in this thesis can be found in 
papers I-IV. In this part I will go into some general concept of methods used in the different 
studies. 
3.1 FLY GENERATION 
We have generated our BRICHOS flies using a system called the φC31 (Bateman et al. 
2006). The advantage of this system is that one can achieve site-specific expression, 
eliminating a number of problems related to random gene insertion such as variable 
expression levels or unwanted insertion into an essential gene. The φC31 integrase is derived 
from the bacteriophage φC31 and encodes a recombinase that mediates site-specific 
recombination between two attachment sites, attB and attP (Thorpe et al. 2000). Insertion of 
the gene of interest can be directed to a specific site by using the attB-sequence in a vector 
and a fly line that has an attP sequence already incorporated into a specific site in the genome. 
For our fly lines we used the pUASTattB vector, a vector based on the pUAST vector (Brand 
and Perrimon 1993) containing five optimized Gal4 binding sites. Our constructs were 
inserted into the vector, which was then sent to BestGene Inc for injection and initial 
cultivation of fly lines. In study II or III we chose to incorporate our BRICHOS genes at site 
86Fb, since this site have a high rate of successful integration (Bischof et al. 2007). The site is 
located on the third chromosome, which was important because most Aβ lines that we used 
have their transgene inserted in the second chromosome, making crossings easier. 
3.2 LONGEVITY ASSAY 
The longevity assays were performed by keeping 10 flies of a genotype per tube at constant 
temperature and humidity, changing the food every 2-3 days and counting the number of flies 
alive. Aβ42 expression in the CNS reduces the life span of the flies compared to control flies 
(Crowther et al. 2005). Variability can be caused by several factors, e.g. the food 
composition, temperature and humidity. If the food is too moist, the flies can get stuck and 
drown, if the food is to dry the flies and larval will be dehydrated. The relative temperature 
and humidity in the incubator also affects the flies’ longevity. Higher temperature induces a 
higher expression of Gal4 (Duffy 2002), leading to increased expression of transgenes and 
possibly higher toxicity. Keeping constant temperatures, humidity levels and regular 
changing the food is essential to decrease the variability. 
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3.3 LOCOMOTOR ACTIVITY 
The locomotor activities of groups of 5 flies were measured by counting the number of flies 
able to climb a certain height in a given time. It has previously been shown that flies 
expressing Aβ42 in the CNS develop age-dependent locomotor deficits compared to control 
flies (Crowther et al. 2005). 
3.4 IMMUNOHISTOCHEMISTRY AND CONFOCAL MICROSCOPY 
To visualize the expression and deposition of the various proteins used in these studies, 
antibody staining and visualization by confocal microscopy was used. Two different methods 
were used for visualization in the fly head and brain. In paper I, the flies were decapitated and 
the heads embedded and frozen in Tissue-Tek O.C.T compound followed by cryosectioning. 
In subsequent steps the sections were fixated and stained with antibodies for analysis by 
confocal microscopy. The advantage of this method is that the whole head can be studied, 
including the eyes and the brain, however due to sectioning the overall three dimensional 
structure is lost. The second method used was to dissect out the brain from the fly heads, 
fixating it and stained with antibodies followed by visualization of the whole brain. In doing 
so, the three dimensional structure of the brain is intact, but surrounding areas such as the fat 
bodies and the eyes cannot be studied. 
3.5 PROXIMITY LIGATION ASSAY 
In order to detect co-localization in tissue samples, we used proximity ligation assay (PLA, 
Olink) (Fredriksson et al. 2002, Soderberg et al. 2006). PLA, like conventional 
immunohistochemistry, uses antibodies, but with higher sensitivity and specificity. In order 
for a PLA signal to occur, dual binding events need to take place. In PLA, primary antibodies 
from two different hosts are used, binding to the same or different targets. Instead of a 
conventional fluorophore, the secondary antibodies are coupled with oligonucleotides, which 
are complementary. If these oligonucleotides are in close proximity, they can be ligated and 
amplified, giving a fluorescence signal. The amplification process results in high sensitivity. 
3.6 THIOFLAVIN T ASSAY 
Thioflavine T (ThT) is a benzothiazole salt that is used for measuring the fibril formation of 
amyloid proteins. When ThT binds to β-sheets its fluorescence emission increases and a 
characteristic red shift in wavelength of emission maximum is seen (LeVine 1999). 
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3.7 CELL APOPTOSIS ASSAY 
Caspase-3 is a member of a group of proteases activated during cellular apoptosis (Taylor et 
al. 2008). The target for caspase-3 is a four amino acid (DXXD) motif. Stable cell lines 
transfected with a vector producing two fluorophores linked by a DXXD sequence can be 
used to monitor caspase-3 activity (Kohler et al. 2003). When the fluorophores are linked to 
each other, fluorescence energy transfer (FRET) occurs and the signal can be measured. 
When apoptosis occurs, caspase-3 cleavage of the linking region results in loss of the FRET 
signal.  
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4 RESULTS 
4.1 PAPER I 
Since wild type TTR is stable in homotetrameric configuration, one can argue that factors that 
can cause a shift into aggregation prone monomers will affect amyloid propensity. HS has 
been associated with several amyloid diseases and found to promote fibril formation. In this 
study we examined the association and effects of HS on TTR. Staining myopathic heart tissue 
from an elderly patient using Congo red showed the characteristic birefringence and staining 
with Alcian Blue, for detection of HS, revealed a similar pattern. TTR and HS therefore seem 
to co-localize in heart tissue, which was supported by using antibodies against TTR and HS. 
The effect of HS on aggregation of TTR was investigated with a ThT assay under acidic 
conditions. The addition of HS to TTR promoted the fibril formation and high sulfated 
heparin increased the fibrillization more than lower sulfated forms of HS. The length of the 
polysaccharide chains also had an effect, and heparin was the overall most effective 
compound in increasing the fibril formation. 
The interaction of TTR and HS was characterized using surface plasmon resonance. The 
binding of heparin to TTR was significantly higher at low pH than at higher pH, and higher 
sulfation degree increased the affinity of HS. By using peptide fragments and full length TTR 
incubated with heparin, the region of binding in TTR was localized to residues 24-35. This 
region contains three basic amino acids, which are likely involved in the interaction with HS. 
Since this region is buried in the native homotetramer of TTR, dissociation into monomers is 
needed for effective binding of HS. 
Comparing wild type and HS-deficient cells incubated with TTR, showed significantly higher 
TTR fibrillization for wild type cells. Finally, we used a Drosophila model expressing 
TTRV14N/V16E, an engineered, aggregation prone variant of TTR. Since the valines are buried 
in a hydrophobic environment in wild type TTR, the exchange to polar residues causes 
destabilization leading to heightened aggregation tendency. The flies were fed with either 
standard media, heparin supplemented food or low molecular weight heparin supplemented 
food. Lysates of the heads from flies fed with heparin supplemented food gave ThT and 
Alcian blue signal, whereas standard media and low molecular weight heparin supplemented 
food did not. Sectioning the heads and staining with antibodies for heparin and TTR revealed 
co-deposition in the retina, which was not present in control flies. 
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 To summarize our findings, HS can be found co-localized with TTR in a myopathic heart 
tissue and the presence of HS seems to promote fibril formation of TTR both in vitro and in 
vivo. In addition, we identified that the region of residues 24-35 of TTR contains the binding 
site of HS and that low pH is necessary for effective binding. 
4.2 PAPER II 
It has previously been shown in vitro that the BRICHOS domain of proSP-C can interact with 
Aβ42 and inhibit its aggregation into fibrils (Johansson et al. 2009, Nerelius et al. 2009a, 
Willander et al. 2012b). To examine proSP-C BRICHOS effects on Aβ42 in a living 
organism, we generated a UAS/Gal4 dependent Drosophila melanogaster model expressing 
the linker region and BRICHOS domain of proSP-C coupled to a signal peptide from lung 
surfactant protein B. We used the φC31 system for site-specific insertion into the 3rd 
chromosome. These flies were crossed with Aβ42 expressing flies with either one or two 
copies of Aβ42 (Crowther et al. 2005). The expression levels were compared using qtPCR, 
which showed no effect on expression levels of Aβ when co-expressing proSP-C BRICHOS. 
Longevity and locomotor assays of non-expressing transgenic flies were also done to ensure 
that the transgenic insertion as such did not affect the flies. 
Expressing Aβ42 in either one or two copies in the CNS of the flies using the ElavC155 driver 
resulted in decreased life span and locomotor activity when compared to control flies, with 
two copies of Aβ42 resulting in higher toxicity. Co-expressing Aβ42 and proSP-C BRICHOS 
showed increased life span and locomotor activity compared to flies only expressing Aβ42. 
The effects of proSP-C BRICHOS on Aβ42 were further studied by dissecting out the brain 
of the flies and staining with antibodies against Aβ and proSP-C BRICHOS. Accumulation of 
Aβ42 was delayed when co-expressed with proSP-C BRICHOS, and proSP-C BRICHOS and 
Aβ42 could furthermore be co-localized in the central parts of the brain. An in vitro 
experiment using electron microscopy showed that proSP-C BRICHOS binds Aβ42 fibrils. 
Finally, we showed that the presence of proSP-C BRICHOS increases the ratio of soluble to 
insoluble Aβ42. 
The results of the study show that proSP-C BRICHOS can have an inhibiting effect on Aβ42 
aggregation and toxicity in vivo. Furthermore, proSP-C BRICHOS was shown to co-localize 
with Aβ fibrils and affect the levels of soluble/insoluble Aβ42. The presence of Aβ42 
deposits at later time points, but without severe toxicity, indicate that proSP-C BRICHOS 
interferes with the formation of toxic species rather than preventing Aβ deposition altogether.  
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4.3 PAPER III 
Having shown that the BRICHOS domain of proSP-C, a lung surfactant protein, could 
prevent toxicity and aggregation of Aβ42 (Paper II), we wanted to examine if the same was 
true for other BRICHOS domains. Previously, we have shown that the BRICHOS domain of 
Bri2 can inhibit fibril formation of Aβ42 in a more efficient way than proSP-C BRICHOS 
(Willander et al. 2012b). 
We generated a fly strain with an insert of residue 90-236 of Bri2 together with a signal 
peptide from lung surfactant protein B. The flies were generated in the same manner as in 
paper II, although in this study, only flies with one copy of Aβ42 were used and different 
food composition, temperature and humidity levels were used. ProSP-C BRICHOS 
expressing flies were also generated to compare effects of two different BRICHOS proteins. 
qtPCR analysis of mRNA levels from fly heads showed that amounts of Aβ42 expressed was 
unaffected by the expression Bri2 BRICHOS. 
Co-expression of Bri2 BRICHOS and Aβ42 showed improved survival over flies expressing 
Aβ42 alone. The expression of Aβ42 reduces the climbing ability of the flies when compared 
to control flies only expressing Gal4. Co-expression of either proSP-C BRICHOS or Bri2 
BRICHOS causes the climbing ability to improve, with Bri2 BRICHOS showing the largest 
improvement.  
Expressing Aβ42 in the eyes of the flies causes malformation and reduced diameter of the 
rhabdomeres of the flies’ ommatidia. These effects can largely be inhibited by co-expression 
of Bri2 BRICHOS, while proSP-C BRICHOS seems to inhibit the reduction of the 
rhabdomers diameter to a somewhat smaller extent. Expression of Bri2 BRICHOS or proSP-
C BRICHOS alone results in no phenotypical changes compared to control flies. 
Localization of BRICHOS and Aβ42 was studied in the fly brain using immunofluorescence 
and confocal microscopy. Interestingly, the staining pattern of flies expressing Aβ42 alone 
and co-expressing Bri2 BRICHOS with Aβ42 was drastically different. In flies only 
expressing Aβ42, the Aβ is detected around the antennal lobes of the fly brain, while co-
expression with Bri2 BRICHOS results in staining in the mushroom bodies, where Aβ42 co-
localizes with Bri2 BRICHOS. Co-expression of proSP-C BRICHOS and Aβ42 instead leads 
to co-localized signal around the antennal lobes and the amount of Aβ42 deposits are 
reduced. Expressing Aβ42 together with GFP as a reporter protein results in no visible 
changes in the mushroom bodies structure compared to control flies. 
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Analyzing the amounts of soluble and insoluble Aβ42, it was seen that co-expression of Bri2 
BRICHOS reduces the amounts of insoluble Aβ42. The soluble level seems largely 
unchanged by the co-expression of Bri2 BRICHOS. 
In summary, Bri2 BRICHOS seems to be more efficient in inhibiting the toxic effects of 
Aβ42 than proSP-C BRICHOS. The difference in localization of Aβ42 in the fly brain 
indicates possible differences in the mechanism of action by the two BRICHOS domains. 
Bri2 BRICHOS ability to prevent Aβ42 toxicity and association to APP and Aβ (Matsuda et 
al. 2008) makes Bri2 BRICHOS a very interesting protein that could be harnessed for AD 
treatment. 
4.4 PAPER IV 
IAPP is a small peptide associated with T2D, which can aggregate and form amyloid fibrils. 
Bri2 is expressed in several tissues in the body and the anti-amyloid mechanism makes it an 
interesting candidate to study in conjunction with IAPP.  
The presence of Bri2 in isolated human islets was shown using extracts and pancreatic 
sections and reactivity seems to appear in the β-cells and co-localize with insulin. However, 
comparing the staining of insulin and Bri2 indicates that Bri2 also is present in other cell 
types in the islets. Bri2 presence was furthermore shown by mRNA analysis, which showed 
that Bri2 is expressed in human islets. Culturing islets from donors in either normal or high 
glucose levels caused the mRNA levels of Bri2 to decrease, while levels of IAPP mRNA 
increased significantly. 
Pancreatic sections from T2D patients were analyzed using PLA, which showed co-
localization of IAPP and Bri2 in islet amyloid deposits. Sections from healthy individuals 
without amyloid deposits showed no co-localization of IAPP and Bri2, suggesting that co-
localization and interaction occurs only in amyloid deposits and not in β-cells. 
Using either ThT or pFTAA assays showed that Bri2 BRICHOS prevents IAPP from forming 
fibrils, even at substochiometric amounts and in the presence of cellular components. 
Bri2 BRICHOS ability to prevent IAPP toxicity was studied using a caspase-3 fluorescence 
energy transfer (FRET) assay. In this assay, addition of IAPP induced apoptosis and this 
effect was concentration dependent. A 1:1, 2:1, 4:1 and 8:1 ratio of IAPP and Bri2 BRICHOS 
reduced the toxic effects. However a 10:1 ratio of IAPP and Bri2 BRICHOS increases the 
toxic effects of IAPP leading to more cell death, which indicates that substochimetric 
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additions of Bri2 BRICHOS can have a negative impact on cell survival, possibly due to 
formation of toxic species of IAPP. 
The possible inhibition of IAPP toxicity by Bri2 BRICHOS was also evaluated in a 
Drosophila melanogaster model. By expressing IAPP and Bri2 BRICHOS in 8 lateral ventral 
neurons of each brain hemisphere of a fly, together with GFP as a reporter protein, the 
number cell nuclei could be counted. IAPP expression alone is toxic and causes a reduction in 
cell nuclei compared to control flies. Co-expression of IAPP and Bri2 BRICHOS increased 
the number of cell nuclei significantly, compared to IAPP only, showing that Bri2 BRICHOS 
can have a rescuing effect in vivo. Bri2 BRICHOS only expression gave no significant 
difference in cell numbers compared to control flies. 
Our study suggests that Bri2 could be associated to IAPP in the amyloid fibril forming 
process in T2D. Bri2 is co-expressed with IAPP and insulin in β-cells and can be co-localized 
with IAPP in T2D patients. Bri2 BRICHOS can also prevent aggregation and fibril formation 
of IAPP in vitro, and also reduce the toxicity of IAPP in cell culture and in vivo in a 
Drosophila model. Taken together, this indicates that Bri2 could reduce aggregation and 
toxicity of IAPP and possibly be used as a novel treatment for T2D. 
 
   

  41 
5 GENERAL DISCUSSION AND FUTURE PERSPECTIVES 
HS has been implicated to play a vital role in several amyloid diseases and shown to promote 
fibril formation. In paper I, we showed that HS is co-localized with TTR in heart tissue of an 
elderly patient and promotes fibrillization in vitro. Moreover, the binding region of TTR was 
identified and we could show decreased fibril formation in HS-deficient cells and co-
localization of heparin and TTR in a Drosophila model. The interactions, binding and co-
localization of HS and TTR can be an important factor in TTR amyloidosis. 
In paper II and III we show that the BRICHOS domain can prevent aggregation and toxicity 
in vivo by using a Drosophila model, reflecting previous in vitro results (Willander et al. 
2012b), Bri2 BRICHOS is seemingly more potent than proSP-C BRICHOS in preventing 
aggregation and toxicity of Aβ42. Interestingly, as seen in the confocal images of the fly 
brain, the distribution pattern of Aβ42 is markedly different when co-expressed with proSP-C 
compared to Bri2 BRICHOS. This could be due to different mechanisms of action. It has 
been shown that proSP-C BRICHOS binds fibrils and prevents secondary nucleation 
specifically (Cohen et al. 2015), while the mechanism of Bri2 is currently being investigated. 
Co-expression of Aβ42 and Bri2 BRICHOS results in Aβ42 distribution in the mushroom 
bodies of the fly brain, which is interesting as this structure plays a important role in olfactory 
learning and memory (Davis 1993, Heisenberg 2003, Busto et al. 2010) and a Drosophila 
APP ortolog, essential for long-term memory (Goguel et al. 2011), is highly enriched in the 
mushroom bodies (Torroja et al. 1996). 
The fibril formation inhibition by the BRICHOS domain has not been explored in detail for 
amyloid proteins other than Aβ, but the BRICHOS domain of proSP-C has also been shown 
to inhibit fibril formation of medin (Nerelius et al. 2009a). Bri2 is expressed in several tissues 
in humans and could therefore be associated with other amyloid diseases than AD. We 
investigated if Bri2 is expressed in pancreatic islets involved in T2D and examined possible 
interactions of Bri2 and IAPP. We found that Bri2 is expressed in the islets and co-localizes 
with IAPP in amyloid deposits. Interestingly no co-localization of IAPP and Bri2 could be 
detected in tissue lacking amyloid deposits, possibly indicating that Bri2 only binds to IAPP 
in aggregated and amyloid form. This is in line with recent findings about the interaction 
between proSP-C BRICHOS and Aβ (Cohen et al. 2015), indicating a possible common 
mechanism for BRICHOS domains in general. We also showed that Bri2 BRICHOS could 
prevent the fibril formation of IAPP for an extended time period in a similar, but more potent, 
manner as seen before with Aβ. Moreover, Bri2 BRICHOS can under certain conditions 
prevent toxicity of IAPP, as seen in cell toxicity assays and the Drosophila model. However, 
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using higher molar ratios of IAPP:Bri2 BRICHOS leads to increased toxicity. Further studies 
are required to determine the basis of this observation, but it could possibly be due to that 
Bri2 BRICHOS slows down the fibril formation process, and thereby extends the time under 
which toxic oligomers are present.  
Utilizing a fly model for studying amyloid diseases is a viable option for looking at 
mechanisms and toxicity in an in vivo system. As mentioned previously, many important 
scientific insights and discoveries have come from the use of Drosophila as a model system. 
Comparing the results in papers I and IV obtained using fly models and human tissue 
sections, one can see that they agree well. In paper I, we showed that TTR can co-localize 
with HS in heart tissue from a myopathic patient. Using a fly model expressing TTR we show 
that by feeding the flies with heparin supplemented food, TTR and HS could be co-localized 
in the fly’s heads. In paper IV we used human cell lines to study toxicity of IAPP and 
likewise, IAPP had a toxic effect on cells when expressed in lateral ventral neurons in a 
Drosophila model. Different amyloid proteins also have potentially different toxic effects, 
which is also reflected in the fly models. In paper II and III we use an Aβ42 fly model that in 
both studies decreases the longevity of the flies when expressed throughout the CNS. IAPP 
on the other hand, has previously been shown not to affect the longevity of the flies when 
expressed in the same way compared to control flies (Schultz et al. 2011). Interestingly, when 
expressing IAPP in the lateral ventral neurons using the pdf driver, IAPP expression 
decreases the number of cell nuclei. However, expression of Aβ42 with the same driver 
results in no significant difference from the control flies (Schultz 2011). As HS also has been 
linked to IAPP aggregation and shown to promote IAPP fibril formation (Watson et al. 1997, 
Castillo et al. 1998), the fly model of IAPP could be used to study this interaction in vivo with 
a similar strategy as used in paper I with TTR and HS. The field of Drosophila research is, as 
all other research fields, ever-evolving, and new genetic tools become available all the time. 
In 1993 the UAS/Gal4 system was introduced and further developed during the subsequent 
years. The last years have introduced techniques such as the CRISPR/Cas9 system (Gratz et 
al. 2013) in the Drosophila, facilitating precise deletion, insertion and sequence replacement 
in fly lines. These genetic tools, together with the many fly models of amyloid diseases 
available, makes Drosophila a viable choice for further studies of amyloidosis in vivo. There 
are of course drawbacks in using Drosophila as a model organism. The flies are small and 
fragile to environmental changes such as temperature or humidity, and due to their size the 
amounts of expressed protein is low, which in turn requires sensitive techniques for analysis. 
In studies with implications for human medicine one must also consider that the flies are 
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much less complex when compared to humans, e.g. their blood brain barrier is rudimentary 
compared to humans. 
The BRICHOS domain models introduced in papers II, III and IV could be used to study 
other aspects of the BRICHOS domain in vivo, or to investigate effects of BRICHOS 
domains on other amyloid proteins, such as TTR or α-synuclein. We have also generated a 
model of proSP-C BRICHOSL188Q, a mutant associated with ILD. This model could be used 
to study how mutations in the BRICHOS domain affect the functionality compared to the 
wild type counterpart in vivo. 
The BRICHOS domain is far from the sole example of a chaperone inhibiting amyloid 
formation. As mentioned previously, HSPs have shown to exhibit similar effects on amyloid 
proteins (Auluck et al. 2002) and in a recent study the molecular chaperone DNAJB6, 
belonging to the DNAJ family, was shown to inhibit both primary and secondary nucleation 
of Aβ42 (Mansson et al. 2014). It has also been shown that non-chaperone proteins can 
exhibit chaperone-like inhibition of Aβ40 aggregation (Luo et al. 2014). The results of this 
thesis suggest that BRICHOS could in the future be used in treatment of AD. One general 
problem in AD treatment is getting a drug across the blood brain barrier. Getting a sizable 
protein domain to cross is challenging, although modern molecular engineering can be used 
to modify drugs for easier transport over the barrier (Pardridge 2012, Pardridge and Boado 
2012). In the case of Bri2 BRICHOS, there could be alternative strategize like cell 
transplantation, or utilizing the endogenous protein, by e.g. upregulating its expression and/or 
modulate the processing of Bri2. As Bri2 is present in several other organs such as the 
pancreas, this could also be applicable for harnessing Bri2 in prevention of other amyloid 
diseases. A natural next step after showing inhibition of Aβ42 and IAPP in Drosophila is to 
continue research in another in vivo model, such as mice. Bri2 has already been shown to 
inhibit aggregation and toxicity of Aβ42 in a mouse model (Kim et al. 2013), however this 
was done with a fusion protein of Aβ42 and Bri2. Expressing Aβ42 in the mice and injecting 
BRICHOS to study possible treatment effects would give a more realistic situation, and could 
also be used to see if BRICHOS is transported across the blood brain barrier to any 
significant extent. Mice with Aβ42 and BRICHOS expressed individually could be 
constructed to study possible effects of upregulation of BRICHOS. There are a number of 
APP-mouse models which could be interesting to used instead of just mouse models 
expressing Aβ, especially seeing as Bri2 has been shown to modulate the processing of APP 
(Fotinopoulou et al. 2005, Matsuda et al. 2005, Matsuda et al. 2008). Several mouse models 
of APP have been created and shown behavioral and pathological characteristics similar to 
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AD (Hsiao et al. 1996, Sturchler-Pierrat et al. 1997). Knock-in models of human APP have 
led to overexpression and artificial phenotypes as a result of other APP fragments are 
overproduced alongside Aβ. A recent mouse model tried to solve this issue by humanizing 
the mouse APP sequence and introducing mutations to increase the ratio of Aβ40/Aβ42 or 
Aβ42/Aβ40 (Saito et al. 2014). The mice showed Aβ accumulation, neuroinflammation and 
memory impairment in an age-dependent manner reminiscent of AD.  
As mentioned previously it was recently shown that increased dissociation of proSP-C 
BRICHOS trimers into monomers, either by substrate addition or mutation, increases the 
inhibition potential against Aβ42 (Biverstal et al. 2015). This further strengthens the 
possibility that the monomer is the active form, but also suggests that modification to 
BRICHOS structure could enhance its capacity for fibril formation inhibition and possibly 
prevention of toxicity. This could be tested in vivo by using a Drosophila model system with 
the same approach as we have used in papers II, III and IV, which would also give an 
important indication if increased dissociation into monomers would cause any side effects. 
Summarizing our results from paper II, III and IV, we have shown that the BRICHOS 
domain can prevent toxicity of amyloid proteins in in vivo model systems. These results show 
that harnessing the effect of the BRICHOS domain against amyloid formation and toxicity 
could provide a novel candidate for pharmaceutical use against amyloid diseases.  
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